Philip E Castle

Summary

Affiliation: National Institutes of Health
Country: USA

Publications

  1. ncbi Contraceptive testing of vaginal agents in rabbits
    P E Castle
    Thomas C Jenkins Department of Biophysics, Johns Hopkins University, Baltimore, Maryland, USA
    Contraception 58:51-60. 1998
  2. ncbi Restricted cross-reactivity of hybrid capture 2 with nononcogenic human papillomavirus types
    Philip E Castle
    Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Maryland 20892, USA
    Cancer Epidemiol Biomarkers Prev 11:1394-9. 2002
  3. ncbi Comparisons of HPV DNA detection by MY09/11 PCR methods
    Philip E Castle
    Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Maryland 20892, USA
    J Med Virol 68:417-23. 2002
  4. ncbi Chlamydia trachomatis, herpes simplex virus 2, and human T-cell lymphotrophic virus type 1 are not associated with grade of cervical neoplasia in Jamaican colposcopy patients
    Philip E Castle
    Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Maryland 20892, USA
    Sex Transm Dis 30:575-80. 2003
  5. ncbi Human monoclonal antibody stability and activity at vaginal pH
    Philip E Castle
    Thomas C Jenkins Department of Biophysics, Johns Hopkins University, Baltimore, MD 21218, USA
    J Reprod Immunol 56:61-76. 2002
  6. ncbi Could multiple low-affinity bonds mediate primary sperm-zona pellucida binding?
    Philip E Castle
    Reproduction 124:29-32. 2002
  7. ncbi Results of human papillomavirus DNA testing with the hybrid capture 2 assay are reproducible
    Philip E Castle
    Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, USA
    J Clin Microbiol 40:1088-90. 2002
  8. ncbi Sexual behavior, human papillomavirus type 16 (HPV 16) infection, and HPV 16 seropositivity
    Philip E Castle
    Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Maryland 20892, USA
    Sex Transm Dis 29:182-7. 2002
  9. ncbi An association of cervical inflammation with high-grade cervical neoplasia in women infected with oncogenic human papillomavirus (HPV)
    P E Castle
    Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, Bethesda, Maryland 20892, USA
    Cancer Epidemiol Biomarkers Prev 10:1021-7. 2001
  10. ncbi Rapid clearance of human papillomavirus and implications for clinical focus on persistent infections
    Ana Cecilia Rodriguez
    Division of Cancer Epidemiology and Genetics, National Cancer Institute, 6120 Executive Blvd, EPS, Rm 5032, Rockville, MD 20852, USA
    J Natl Cancer Inst 100:513-7. 2008

Detail Information

Publications102 found, 100 shown here

  1. ncbi Contraceptive testing of vaginal agents in rabbits
    P E Castle
    Thomas C Jenkins Department of Biophysics, Johns Hopkins University, Baltimore, Maryland, USA
    Contraception 58:51-60. 1998
    ..We review the pertinent literature and report findings that provide guidance for effectively using and improving the rabbit contraceptive model in testing new vaginal products...
  2. ncbi Restricted cross-reactivity of hybrid capture 2 with nononcogenic human papillomavirus types
    Philip E Castle
    Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Maryland 20892, USA
    Cancer Epidemiol Biomarkers Prev 11:1394-9. 2002
    ....
  3. ncbi Comparisons of HPV DNA detection by MY09/11 PCR methods
    Philip E Castle
    Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Maryland 20892, USA
    J Med Virol 68:417-23. 2002
    ..Our data also suggest that studies reporting HPV DNA detection by PCR need to report the type of polymerase used, as well as other assay specifics, and underscore the need for worldwide standards of testing...
  4. ncbi Chlamydia trachomatis, herpes simplex virus 2, and human T-cell lymphotrophic virus type 1 are not associated with grade of cervical neoplasia in Jamaican colposcopy patients
    Philip E Castle
    Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Maryland 20892, USA
    Sex Transm Dis 30:575-80. 2003
    ..A few recent studies have suggested that other sexually transmitted infections may increase the likelihood of a human papillomavirus (HPV) infection progressing to high-grade cervical neoplasia and cancer...
  5. ncbi Human monoclonal antibody stability and activity at vaginal pH
    Philip E Castle
    Thomas C Jenkins Department of Biophysics, Johns Hopkins University, Baltimore, MD 21218, USA
    J Reprod Immunol 56:61-76. 2002
    ..Taken together, our data and empirical calculations suggest that vaginally applied human MAbs are likely to remain stable and active throughout the duration they are likely to reside in the vagina...
  6. ncbi Could multiple low-affinity bonds mediate primary sperm-zona pellucida binding?
    Philip E Castle
    Reproduction 124:29-32. 2002
    ..A mechanism involving multiple low-affinity bonds could account for some of the difficulties in elucidating primary sperm-zona pellucida interactions...
  7. ncbi Results of human papillomavirus DNA testing with the hybrid capture 2 assay are reproducible
    Philip E Castle
    Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, USA
    J Clin Microbiol 40:1088-90. 2002
    ..68 and the linear-weighted kappa was 0.76. The results of this study indicate that HC 2 testing is reproducible even among cytologically normal women with low test values...
  8. ncbi Sexual behavior, human papillomavirus type 16 (HPV 16) infection, and HPV 16 seropositivity
    Philip E Castle
    Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Maryland 20892, USA
    Sex Transm Dis 29:182-7. 2002
    ..Sexual behaviors have been linked to seropositivity for human papillomavirus (HPV) but not with the magnitude of the seroreactivity...
  9. ncbi An association of cervical inflammation with high-grade cervical neoplasia in women infected with oncogenic human papillomavirus (HPV)
    P E Castle
    Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, Bethesda, Maryland 20892, USA
    Cancer Epidemiol Biomarkers Prev 10:1021-7. 2001
    ..90-4.1). The results of this study suggest that cervical inflammation may be associated with high-grade lesions and may be a cofactor for high-grade cervical lesions in women infected with oncogenic HPV...
  10. ncbi Rapid clearance of human papillomavirus and implications for clinical focus on persistent infections
    Ana Cecilia Rodriguez
    Division of Cancer Epidemiology and Genetics, National Cancer Institute, 6120 Executive Blvd, EPS, Rm 5032, Rockville, MD 20852, USA
    J Natl Cancer Inst 100:513-7. 2008
    ..These findings suggest that the medical community should emphasize persistence of cervical HPV infection, not single-time detection of HPV, in management strategies and health messages...
  11. ncbi A population-based study of vaginal human papillomavirus infection in hysterectomized women
    Philip E Castle
    Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Department of Health and Human Services, Bethesda, Maryland 20892 7234, USA
    J Infect Dis 190:458-67. 2004
    ..e., A3/A4/A15) may have a predilection for vaginal epithelium...
  12. ncbi Baseline cytology, human papillomavirus testing, and risk for cervical neoplasia: a 10-year cohort analysis
    Mark E Sherman
    Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    J Natl Cancer Inst 95:46-52. 2003
    ..We evaluated whether simultaneous screening with a Pap test and human papillomavirus (HPV) testing is useful for assessing the risk for cervical intraepithelial neoplasia (CIN) 3 or cervical cancer...
  13. ncbi The elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of type-specific HPV testing in clinical practice
    Michelle J Khan
    Division of Cancer Epidemiology and Genetics, National Cancer Institute, 6120 Executive Blvd, Rm. 7074, Rockville, MD 20852, USA
    J Natl Cancer Inst 97:1072-9. 2005
    ..CONCLUSIONS: HPV screening that distinguishes HPV16 and HPV18 from other oncogenic HPV types may identify women at the greatest risk of > or = CIN3 and may permit less aggressive management of other women with oncogenic HPV infections...
  14. ncbi Relationships of human papillomavirus type, qualitative viral load, and age with cytologic abnormality
    Melinda Butsch Kovacic
    Division of Cancer Epidemiology and Genetics and Cancer Prevention Fellowship Program, National Cancer Institute, NIH, Bethesda, Maryland 20892, USA
    Cancer Res 66:10112-9. 2006
    ..The lack of evident severe abnormalities associated with HPV18 and related HPV types might have implications for screening for poorly detected glandular and alpha7-related lesions...
  15. ncbi Short term persistence of human papillomavirus and risk of cervical precancer and cancer: population based cohort study
    Philip E Castle
    Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, DHHS, Bethesda, MD 20892, USA
    BMJ 339:b2569. 2009
    ....
  16. ncbi A comparison of cervical and vaginal human papillomavirus
    Philip E Castle
    Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, Bethesda, MD 20892 7234, USA
    Sex Transm Dis 34:849-55. 2007
    ..Previous studies have failed to present data on or detect a broad spectrum of HPV genotypes and/or have not carefully sampled the vagina, instead relying on self-collection that is likely contaminated with cervical cells...
  17. ncbi Human papillomavirus testing in the prevention of cervical cancer
    Mark Schiffman
    Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD, USA
    J Natl Cancer Inst 103:368-83. 2011
    ..The greatest potential for reduction in cervical cancer rates from HPV screening is in low-resource regions that can implement infrequent rounds of low-cost HPV testing and treatment...
  18. ncbi Neither one-time negative screening tests nor negative colposcopy provides absolute reassurance against cervical cancer
    Philip E Castle
    Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, Bethesda, MD 20892 7234, USA
    Int J Cancer 125:1649-56. 2009
    ....
  19. ncbi Age-related changes of the cervix influence human papillomavirus type distribution
    Philip E Castle
    Division of Cancer Epidemiology and Genetics, National Cancer Institute NIH, 6120 Executive Boulevard, Bethesda, MD 20892 7234, USA
    Cancer Res 66:1218-24. 2006
    ..These patterns need to be confirmed in other studies and populations. We suggest that these genetically distinct groups of HPV types may differ in tissue preferences, which may contribute to their differences in carcinogenic potential...
  20. ncbi A comparison of linear array and hybrid capture 2 for detection of carcinogenic human papillomavirus and cervical precancer in ASCUS-LSIL triage study
    Patti E Gravitt
    Department of Epidemiology and Molecular Microbiology, Johns Hopkins University, Baltimore, Maryland, USA
    Cancer Epidemiol Biomarkers Prev 17:1248-54. 2008
    ..We were interested in comparing the performance of Linear Array (LA; Roche Molecular Systems) to Hybrid Capture 2 (hc2; Digene) for the detection of carcinogenic human papillomavirus (HPV) and cervical precancer...
  21. ncbi Long-term persistence of prevalently detected human papillomavirus infections in the absence of detectable cervical precancer and cancer
    Philip E Castle
    Division of Cancer Epidemiology and Genetics, Department of Health and Human Services, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892 7234, USA
    J Infect Dis 203:814-22. 2011
    ..Detailed descriptions of long-term persistence of human papillomavirus (HPV) in the absence of cervical precancer are lacking...
  22. ncbi Human papillomavirus genotype attribution and estimation of preventable fraction of anal intraepithelial neoplasia cases among HIV-infected men who have sex with men
    Vikrant V Sahasrabuddhe
    Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Rockville, Maryland 20852, USA
    J Infect Dis 207:392-401. 2013
    ....
  23. ncbi Immune profiling of plasma and cervical secretions using recycling immunoaffinity chromatography
    Philip E Castle
    Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Department of Health and Human Services, Bethesda, Maryland 20892 7234, USA
    Cancer Epidemiol Biomarkers Prev 12:1449-56. 2003
    ....
  24. ncbi A study of Amplicor human papillomavirus DNA detection in the atypical squamous cells of undetermined significance-low-grade squamous intraepithelial lesion triage study
    Nicolas Wentzensen
    Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, MD 20854 7234, USA
    Cancer Epidemiol Biomarkers Prev 18:1341-9. 2009
    ..Amplicor at the 1.5 cutoff had comparable performance with hc2. Whereas Amplicor missed more disease related to nontargeted types, hc2 was more likely to miss disease related to targeted types...
  25. ncbi A prospective study of age trends in cervical human papillomavirus acquisition and persistence in Guanacaste, Costa Rica
    Philip E Castle
    Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Department of Health and Human Services, Bethesda, Maryland 20892 7234, USA
    J Infect Dis 191:1808-16. 2005
    ..In some populations, HPV prevalence demonstrates a second peak in older women. Longitudinal data may help to explain this second peak...
  26. ncbi Human papillomavirus (HPV) genotypes in women with cervical precancer and cancer at Kaiser Permanente Northern California
    Philip E Castle
    Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, DHHS, Bethesda, Maryland, USA
    Cancer Epidemiol Biomarkers Prev 20:946-53. 2011
    ..Here, we present the HPV genotypes found in first ∼500 cases of cervical intraepithelial neoplasia grade 3 (CIN3) or more severe disease (CIN3+) diagnosed at the study baseline...
  27. ncbi Human papillomavirus prevalence in women who have and have not undergone hysterectomies
    Philip E Castle
    Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Department of Health and Human Services, Rockville, MD, USA
    J Infect Dis 194:1702-5. 2006
    ..5% for WH) between the 2 groups of women. Although WH have a similar prevalence of carcinogenic HPV infection, compared with WNH without a cervix, they have minimal risk of HPV-induced cancer and are unlikely to benefit from HPV testing...
  28. ncbi A long-term prospective study of type-specific human papillomavirus infection and risk of cervical neoplasia among 20,000 women in the Portland Kaiser Cohort Study
    Mark Schiffman
    Clinical Genetics Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, Bethesda, MD 20892, USA
    Cancer Epidemiol Biomarkers Prev 20:1398-409. 2011
    ..Adding HPV testing to cytology is recommended for women ≥30 but long-term prospective studies of HPV testing are rare...
  29. ncbi Comparison between prototype hybrid capture 3 and hybrid capture 2 human papillomavirus DNA assays for detection of high-grade cervical intraepithelial neoplasia and cancer
    Philip E Castle
    Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, Bethesda, Maryland 20892, USA
    J Clin Microbiol 41:4022-30. 2003
    ..68 to 0.79). In conclusion, we suggest that HC3 (>/=0.6 RLU/PC) may be slightly more sensitive than and equally specific test as HC2 (>/=1.0 RLU/PC) for the detection of CIN3+ over the duration of typical screening intervals...
  30. ncbi Human papillomavirus testing following loop electrosurgical excision procedure identifies women at risk for posttreatment cervical intraepithelial neoplasia grade 2 or 3 disease
    Aimee R Kreimer
    National Cancer Institute, NIH, 6130 Executive Boulevard, Bethesda, MD 20892 7333, USA
    Cancer Epidemiol Biomarkers Prev 15:908-14. 2006
    ....
  31. ncbi A prospective study of high-grade cervical neoplasia risk among human papillomavirus-infected women
    Philip E Castle
    National Cancer Institute, Division of Cancer Epidemiology and Genetics, Bethesda, MD 20892, USA
    J Natl Cancer Inst 94:1406-14. 2002
    ..However, these potential risk factors have not been adequately studied in prospective studies...
  32. ncbi Methylation of HPV18, HPV31, and HPV45 genomes and cervical intraepithelial neoplasia grade 3
    Nicolas Wentzensen
    Division of Cancer Epidemiology and Genetics, National Cancer Institute, 6120 Executive Blvd, Room 5024, Rockville, MD 20852 7234, USA
    J Natl Cancer Inst 104:1738-49. 2012
    ..However, the extent of methylation in other HPV types and its role in progression to cancer is poorly understood...
  33. ncbi Comparative performance of human papillomavirus DNA testing using novel sample collection methods
    Julia C Gage
    Clinical Genetics Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, 6120 Executive Blvd, MSC 7231, Rockville, MD 20852, USA
    J Clin Microbiol 49:4185-9. 2011
    ..HC2 is likely more clinically specific, although possibly less sensitive, than either PCR test. Thus, use of HC2 on cervicovaginal specimens for screening could result in fewer referrals compared to LA and Amplicor...
  34. ncbi Comparison of the cobas Human Papillomavirus (HPV) test with the hybrid capture 2 and linear array HPV DNA tests
    Julia C Gage
    Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, DHHS, Bethesda, Maryland, USA
    J Clin Microbiol 50:61-5. 2012
    ..Additional studies are needed to compare HC2 and cobas for detecting and predicting CIN3 to understand the clinical implications of the discrepant test results between the two tests...
  35. ncbi Comparison of two PCR-based human papillomavirus genotyping methods
    Philip E Castle
    Division of Cancer Epidemiology and Genetics, National Cancer Institute, 6120 Executive Blvd, Room 5004, EPS MSC 7234, Bethesda, MD 20892 7234
    J Clin Microbiol 46:3437-45. 2008
    ..Both approaches are suitable for monitoring the impact of HPV16/18 vaccines in clinical trials...
  36. ncbi Human papillomavirus type 16 infections and 2-year absolute risk of cervical precancer in women with equivocal or mild cytologic abnormalities
    Philip E Castle
    Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, DHHS, Bethesda, MD 20892 7234, USA
    J Natl Cancer Inst 97:1066-71. 2005
    ....
  37. ncbi Variable risk of cervical precancer and cancer after a human papillomavirus-positive test
    Philip E Castle
    Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Department of Health and Human Services, Bethesda, Maryland 20892 7234, USA
    Obstet Gynecol 117:650-6. 2011
    ..To explore the effect of screening history on the risk of cervical precancer and cancer after an human papillomavirus (HPV)-positive test...
  38. ncbi Hierarchical clustering of human papilloma virus genotype patterns in the ASCUS-LSIL triage study
    Nicolas Wentzensen
    Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, Maryland 20852 7234, USA
    Cancer Res 70:8578-86. 2010
    ..Our novel approach to study multiple genotype infections in cervical disease with the use of unsupervised hierarchical clustering can address complex genotype distributions on a population level...
  39. ncbi Seroreactivity to human papillomavirus (HPV) types 16, 18, or 31 and risk of subsequent HPV infection: results from a population-based study in Costa Rica
    Raphael P Viscidi
    Johns Hopkins University School of Medicine, Baltimore, Maryland 21287, USA
    Cancer Epidemiol Biomarkers Prev 13:324-7. 2004
    ..3; 95% CI 1.0-1.8). Thus, we did not observe immunity, although a protective effect from natural infection cannot be excluded because of the limits of available assays and study designs...
  40. ncbi Absolute risk of a subsequent abnormal pap among oncogenic human papillomavirus DNA-positive, cytologically negative women
    Philip E Castle
    Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, Maryland, USA
    Cancer 95:2145-51. 2002
    ..The absolute risk of a subsequent abnormal Pap test for these women is uncertain. Therefore, the proper counseling and clinical management of these women is also uncertain...
  41. ncbi Cervical cancer risk for women undergoing concurrent testing for human papillomavirus and cervical cytology: a population-based study in routine clinical practice
    Hormuzd A Katki
    Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, DHHS, Bethesda, MD 20882, USA
    Lancet Oncol 12:663-72. 2011
    ....
  42. ncbi Smoking is a risk factor for cervical intraepithelial neoplasia grade 3 among oncogenic human papillomavirus DNA-positive women with equivocal or mildly abnormal cytology
    Kathleen McIntyre-Seltman
    Division of Cancer Epidemiology and Genetics, National Cancer Institute, Room 7074, 6120 Executive Boulevard, EPS MSC 7234, Bethesda, MD 20892-7234, USA
    Cancer Epidemiol Biomarkers Prev 14:1165-70. 2005
    ..Smoking cessation trials targeting this population might be warranted...
  43. ncbi PCR testing of pooled longitudinally collected cervical specimens of women to increase the efficiency of studying human papillomavirus infection
    Philip E Castle
    Division of Cancer Epidemiology and Genetics, National Cancer Institute, Room 7074, 6120 Executive Boulevard, EPS MSC 7234, Bethesda, MD 20892 7234, USA
    Cancer Epidemiol Biomarkers Prev 14:256-60. 2005
    ..3% (95% CI, 74.7-91.4%), respectively. We conclude that pooling specimens and testing by PCR may be useful for discriminating HPV DNA-positive from completely negative specimen sets in women who are likely to have been HPV DNA-negative.>..
  44. ncbi Risk assessment to guide the prevention of cervical cancer
    Philip E Castle
    Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Department of Health and Human Services, Bethesda, MD 20892 7234, USA
    J Low Genit Tract Dis 12:1-7. 2008
    ....
  45. ncbi Influence of loop electrosurgical excision procedure on subsequent acquisition of new human papillomavirus infections
    Philip E Castle
    Divisions of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
    J Infect Dis 199:1612-20. 2009
    ..The impact of loop electrosurgical excision procedure (LEEP) treatment for cervical precancerous lesions on subsequent acquisition of new human papillomavirus (HPV) infections is not well described...
  46. ncbi Effect of the number of biopsies on the subsequent acquisition of new human papillomavirus infections
    Philip E Castle
    National Cancer Institute, National Institutes of Health, Department of Health and Human Services, Bethesda, MD, USA
    Obstet Gynecol 114:1057-62. 2009
    ..To analyze the effect of number of biopsies taken at enrollment with incident human papillomavirus (HPV) infections detected at the next 6-month visit...
  47. ncbi A population-based prospective study of carcinogenic human papillomavirus variant lineages, viral persistence, and cervical neoplasia
    Mark Schiffman
    Divisions of Cancer Epidemiology and Genetics and Cancer Prevention, National Cancer Institute, Bethesda, Maryland 20852, USA
    Cancer Res 70:3159-69. 2010
    ..Larger viral genomic studies are warranted, especially to identify the genetic basis for HPV16's unique carcinogenicity...
  48. ncbi The age-specific relationships of abnormal cytology and human papillomavirus DNA results to the risk of cervical precancer and cancer
    Philip E Castle
    Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Department of Health and Human Services, Bethesda, Maryland, USA
    Obstet Gynecol 116:76-84. 2010
    ..To estimate the relationship of human papillomavirus (HPV) detection and abnormal cytology with histologic diagnoses of cervical precancer and cancer...
  49. ncbi Comparison of measurements of human papillomavirus persistence for postcolposcopic surveillance for cervical precancerous lesions
    Julia C Gage
    Clinical Genetics Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, 6120 Executive Boulevard, EPS 7013, Rockville, MD 20852, USA
    Cancer Epidemiol Biomarkers Prev 19:1668-74. 2010
    ..Compared with pooled-probe testing, measuring HPV genotype-specific persistence might better predict subsequent grade 3 cervical intraepithelial neoplasia (CIN3)...
  50. ncbi Human papillomavirus genotyping, human papillomavirus mRNA expression, and p16/Ki-67 cytology to detect anal cancer precursors in HIV-infected MSM
    Nicolas Wentzensen
    Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Rockville, MD 20852, USA
    AIDS 26:2185-92. 2012
    ..Both approaches have limited reproducibility and sensitivity for detecting anal cancer precursors. We evaluated biomarkers for human papillomavirus (HPV)-related disease in a population of HIV-infected MSM...
  51. ncbi Human papillomavirus genotype specificity of hybrid capture 2
    Philip E Castle
    Division of Cancer Epidemiology and Genetics, National Cancer Institute, 6120 Executive Blvd, Room 5030, EPS MSC 7234, Bethesda, MD 20892 7234, USA
    J Clin Microbiol 46:2595-604. 2008
    ..In conclusion, hc2 cross-reacts with certain untargeted, noncarcinogenic HPV genotypes that are phylogenetically related to the targeted genotypes, but the degree of cross-reactivity may be less than previously reported...
  52. ncbi Stability of archived liquid-based cervical cytologic specimens
    Philip E Castle
    The National Cancer Institute, Division of Cancer Epidemiology and Genetics, Rockville, Maryland 20892 7234, USA
    Cancer 99:89-96. 2003
    ..However, long-term DNA stability and cytologic stability of these biospecimens have not been evaluated...
  53. ncbi Polycyclic aromatic hydrocarbon-DNA adducts in cervix of women infected with carcinogenic human papillomavirus types: an immunohistochemistry study
    M Margaret Pratt
    Carcinogen DNA Interactions Section, LCBG, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, MD, USA
    Mutat Res 624:114-23. 2007
    ..Therefore, PAH-DNA adduct formation as measured by this methodology did not appear related to the increased risk of cervical precancer and cancer among carcinogenic HPV-infected smokers...
  54. ncbi Interlaboratory reliability of Hybrid Capture 2
    Philip E Castle
    Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, DHHS, Bethesda, MD, USA
    Am J Clin Pathol 122:238-45. 2004
    ..73); among those with equivocal or abnormal cytologic findings, kappa values were 0.80 or more. These data show that HC2 is a reliable test for detecting clinically relevant oncogenic HPV DNA...
  55. ncbi Five-year risks of CIN 3+ and cervical cancer among women with HPV-positive and HPV-negative high-grade Pap results
    Hormuzd A Katki
    Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health DHHS, Bethesda, MD 20892, USA
    J Low Genit Tract Dis 17:S50-5. 2013
    ..We examined whether HPV testing provides useful risk stratification in this context...
  56. ncbi Five-year risks of CIN 3+ and cervical cancer among women who test Pap-negative but are HPV-positive
    Hormuzd A Katki
    Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health DHHS, Bethesda, MD 20892, USA
    J Low Genit Tract Dis 17:S56-63. 2013
    ..However, the performance of these guidelines in routine clinical practice has not been evaluated...
  57. ncbi Follow-up testing after colposcopy: five-year risk of CIN 2+ after a colposcopic diagnosis of CIN 1 or less
    Hormuzd A Katki
    Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health DHHS, Bethesda, MD 20892, USA
    J Low Genit Tract Dis 17:S69-77. 2013
    ..An important question is how many subsequent negative Pap results, or negative Pap and human papillomavirus (HPV) cotest results, are needed before returning to an extended retesting interval...
  58. ncbi Five-year risk of recurrence after treatment of CIN 2, CIN 3, or AIS: performance of HPV and Pap cotesting in posttreatment management
    Hormuzd A Katki
    Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health DHHS, Bethesda, MD 20892, USA
    J Low Genit Tract Dis 17:S78-84. 2013
    ..It is not clear how many negative posttreatment Pap or cotest results are needed to ensure adequate safety against CIN 2+ before returning to extended retesting intervals...
  59. ncbi Hormonal contraceptive use, pregnancy and parity, and the risk of cervical intraepithelial neoplasia 3 among oncogenic HPV DNA-positive women with equivocal or mildly abnormal cytology
    Philip E Castle
    Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, DHHS, Bethesda, MD 20892, USA
    Int J Cancer 117:1007-12. 2005
    ....
  60. ncbi Human papillomavirus genotypes in cervical intraepithelial neoplasia grade 3
    Philip E Castle
    Division of Cancer Epidemiology and Genetics, National Cancer Institute, 6120 Executive Boulevard, Room 5004, MSC 7234, Bethesda, MD 20892 7234, USA
    Cancer Epidemiol Biomarkers Prev 19:1675-81. 2010
    ..There are few large case series describing the human papillomavirus (HPV) genotypes found in women diagnosed with rigorously reviewed cervical intraepithelial neoplasia grade 3 (CIN3), cervical precancer...
  61. ncbi A comparison of a prototype PCR assay and hybrid capture 2 for detection of carcinogenic human papillomavirus DNA in women with equivocal or mildly abnormal papanicolaou smears
    Mark Schiffman
    Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Department of Health and Human Services, Bethesda, MD 20892-7234, USA
    Am J Clin Pathol 124:722-32. 2005
    ..Smaller amounts of material used in PCR could have limited its sensitivity, but our results demonstrate the importance of optimization and standardization of PCR-based assays for clinical applications...
  62. ncbi Viral determinants of human papillomavirus persistence following loop electrical excision procedure treatment for cervical intraepithelial neoplasia grade 2 or 3
    Aimee R Kreimer
    Division of Cancer Prevention, National Cancer Institute, NIH, Bethesda, Maryland 20892, USA
    Cancer Epidemiol Biomarkers Prev 16:11-6. 2007
    ..Data from Atypical Squamous Cells of Undetermined Significance-Low-Grade Squamous Intraepithelial Lesion Triage Study were used to evaluate HPV persistence and reappearance after LEEP...
  63. ncbi Detection of precancerous cervical lesions is differential by human papillomavirus type
    Mahboobeh Safaeian
    Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, Bethesda, Maryland, USA
    Cancer Res 69:3262-6. 2009
    ..001). These results indicate the underrepresentation of HPV18/45 in precancers, whereas HPV16-associated CIN3+ is diagnosed much earlier. Whether the underrepresentation of 18/45 may be due to occult pathology needs further investigation...
  64. ncbi Factors influencing histologic confirmation of high-grade squamous intraepithelial lesion cytology
    Philip E Castle
    Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Department of Health and Human Services, Bethesda, Maryland, USA
    Obstet Gynecol 112:637-45. 2008
    ..To examine the predictors of histologic confirmation of high-grade squamous intraepithelial lesion (HSIL) cytology occurring in follow-up of young women originally referred into a trial because of less severe cytology...
  65. ncbi Hybrid capture 2 viral load and the 2-year cumulative risk of cervical intraepithelial neoplasia grade 3 or cancer
    Philip E Castle
    Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Department of Health and Human Services, Bethesda, MD, USA
    Am J Obstet Gynecol 191:1590-7. 2004
    ....
  66. ncbi Comparison of linear array and line blot assay for detection of human papillomavirus and diagnosis of cervical precancer and cancer in the atypical squamous cell of undetermined significance and low-grade squamous intraepithelial lesion triage study
    Philip E Castle
    Division of Cancer Epidemiology and Genetics, National Cancer Institute, 6120 Executive Blvd, Room 5004, EPS MSC 7234, Bethesda, MD 20892 7234, USA
    J Clin Microbiol 46:109-17. 2008
    ..In conclusion, we found LA to be a promising assay for the detection of HPV genotypes and carcinogenic HPV, and it may be clinically useful for the detection of cervical precancer and cancer in women with equivocal cytology...
  67. ncbi Comparison of ophthalmic sponges for measurements of immune markers from cervical secretions
    Philip E Castle
    Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Department of Health and Human Services, Bethesda, Maryland 20892 7234, USA
    Clin Diagn Lab Immunol 11:399-405. 2004
    ..These findings require confirmation...
  68. ncbi A cross-sectional study of a prototype carcinogenic human papillomavirus E6/E7 messenger RNA assay for detection of cervical precancer and cancer
    Philip E Castle
    Division of Cancer Epidemiology, National Cancer Institute, NIH, Department of Health and Human Services, Bethesda, Maryland 20892 7234, USA
    Clin Cancer Res 13:2599-605. 2007
    ..To evaluate carcinogenic human papillomavirus (HPV) mRNA for E6 and E7 mRNA detection on clinical specimens to identify women with cervical precancer and cancer...
  69. ncbi Relationship of atypical glandular cell cytology, age, and human papillomavirus detection to cervical and endometrial cancer risks
    Philip E Castle
    Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Department of Health and Human Services, Bethesda, Maryland 20892 7234, USA
    Obstet Gynecol 115:243-8. 2010
    ....
  70. ncbi The carcinogenicity of human papillomavirus types reflects viral evolution
    Mark Schiffman
    Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, US Department of Health and Human Services, Bethesda, MA, USA
    Virology 337:76-84. 2005
    ..These results present several clear clues and research directions in our ongoing efforts to understand HPV carcinogenesis...
  71. ncbi A novel filtration-based processing method of liquid cytology specimens for human papillomavirus DNA testing by hybrid capture II
    Philip E Castle
    Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institute of Health, Department of Health and Human Services, Bethesda, MD 20892-7234, USA
    Am J Clin Pathol 123:250-5. 2005
    ..NPM reduces specimen handling and decreases total testing time by approximately 33% without significant losses in HCII test performance...
  72. ncbi The promise of global cervical-cancer prevention
    Mark Schiffman
    Hormonal and Reproductive Epidemiology Branch, Division of Cancer Epidemiology and Prevention, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
    N Engl J Med 353:2101-4. 2005
  73. ncbi An analysis of high-risk human papillomavirus DNA-negative cervical precancers in the ASCUS-LSIL Triage Study (ALTS)
    Philip E Castle
    Division of Cancer Epidemiology and Genetics and Division of Cancer Prevention, National Cancer Institute, National Institutes of Health, Department of Health and Human Services, Bethesda, Maryland, USA
    Obstet Gynecol 111:847-56. 2008
    ....
  74. ncbi Reactivity of human sera in a sensitive, high-throughput pseudovirus-based papillomavirus neutralization assay for HPV16 and HPV18
    Diana V Pastrana
    Laboratory of Cellular Oncology, National Cancer Institute, Bethesda, MD 20892-4263, USA
    Virology 321:205-16. 2004
    ..The SEAP pseudovirus-based neutralization assay should be a practical method for quantifying potentially protective antibody responses in HPV natural history and prophylactic vaccine studies...
  75. ncbi A pilot analytic study of a research-level, lower-cost human papillomavirus 16, 18, and 45 test
    Hannah P Yang
    Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, Bethesda, MD 20892 7234, USA
    J Virol Methods 176:112-4. 2011
    ..It is concluded that the HPV16/18/45 assay is a promising triage test with a minimum detection of approximately 5000 viral copies, the clinically relevant threshold...
  76. ncbi Cervical concentrations of interleukin-10 and interleukin-12 do not correlate with plasma levels
    Philip E Castle
    Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, Maryland 20892 7234, USA
    J Clin Immunol 22:23-7. 2002
    ....
  77. ncbi Detection of cervical cancer and its precursors by endocervical curettage in 13,115 colposcopically guided biopsy examinations
    Julia C Gage
    Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, 6120 Executive Boulevard, Rockville, MD 20892, USA
    Am J Obstet Gynecol 203:481.e1-9. 2010
    ..ECC is routinely performed in the Calgary Health Region colposcopy clinics, permitting a look at its real-world utility...
  78. ncbi Human papillomavirus: epidemiology and public health
    Mark Schiffman
    Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Department of Health and Human Services, Rockville, MD 20852, USA
    Arch Pathol Lab Med 127:930-4. 2003
    ....
  79. ncbi Effects of electron-beam irradiation on buccal-cell DNA
    Philip E Castle
    Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD 20892, USA
    Am J Hum Genet 73:646-51. 2003
    ....
  80. ncbi Evaluation of a prototype real-time PCR assay for carcinogenic human papillomavirus (HPV) detection and simultaneous HPV genotype 16 (HPV16) and HPV18 genotyping
    Philip E Castle
    Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, DHHS, Bethesda, MD 20892 7234, USA
    J Clin Microbiol 47:3344-7. 2009
    ..7% (95% confidence interval, 92.5 to 96.5%). The Linear Array test was more likely than cobas 4800 HPV test to test positive for the 12 other carcinogenic HPV genotypes among women without evidence of cervical disease (P = 0.004)...
  81. ncbi Increasing incidence of testicular germ cell tumors among black men in the United States
    Katherine A McGlynn
    Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Department of Health and Human Services, 6120 Executive Blvd, Rm 7060, Rockville, MD 20852 7234, USA
    J Clin Oncol 23:5757-61. 2005
    ..However, a recent examination of ethnic-specific rates suggested that the incidence among black men may have begun to change in the 1990s...
  82. ncbi Immunohistochemical evaluation of heat shock proteins in normal and preinvasive lesions of the cervix
    Philip E Castle
    Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, DHHS, Bethesda, MD, USA
    Cancer Lett 229:245-52. 2005
    ..We conclude that HSP40, HSP60, and HSP70 expressions are up-regulated in response to the development of CIN3 akin to p16INK4a expression...
  83. ncbi Interobserver agreement in the evaluation of digitized cervical images
    Jose Jeronimo
    Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Maryland 20852, USA
    Obstet Gynecol 110:833-40. 2007
    ..To estimate the agreement among multiple expert colposcopists evaluating high-resolution digitized cervigrams taken from patients with a variety of human papillomavirus (HPV) infection states and previous cervigram interpretations...
  84. ncbi The relationship of community biopsy-diagnosed cervical intraepithelial neoplasia grade 2 to the quality control pathology-reviewed diagnoses: an ALTS report
    Philip E Castle
    Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD 20892 7234, USA
    Am J Clin Pathol 127:805-15. 2007
    ....
  85. ncbi Evidence for frequent regression of cervical intraepithelial neoplasia-grade 2
    Philip E Castle
    Divisions of Cancer Epidemiology and Genetics, National Institutes of Health, Department of Health and Human Services, Bethesda, Maryland, USA
    Obstet Gynecol 113:18-25. 2009
    ....
  86. ncbi Risk assessment to guide the prevention of cervical cancer
    Philip E Castle
    Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Department of Health and Human Services, Bethesda, MD 20892 7234, USA
    Am J Obstet Gynecol 197:356.e1-6. 2007
    ....
  87. ncbi Pilot study of a commercialized human papillomavirus (HPV) genotyping assay: comparison of HPV risk group to cytology and histology
    Philip E Castle
    Division of Cancer Epidemiology, National Cancer Institute, NIH, DHHS, Bethesda, MD 20892 7234, USA
    J Clin Microbiol 44:3915-7. 2006
    ..0005) and histologic diagnoses (P(Trend) < 0.0005)...
  88. ncbi Cervical cancer prevention--cervical screening: science in evolution
    Mahboobeh Safaeian
    Hormonal and Reproductive Epidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health DHHS, 6120 Executive Blvd, Rockville, MD 20852, USA
    Obstet Gynecol Clin North Am 34:739-60, ix. 2007
    ..This article describes the traditional methods of screening for cervical cancer and innovative methods that might help overcome financial and cultural barriers to more widespread screening...
  89. ncbi Detection of carcinogenic human papillomavirus in specimens collected with a novel self-sampling device
    Philip E Castle
    Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD 20892 7234, USA
    J Clin Microbiol 44:2158-9. 2006
    ..The kappa value was 0.66 (95% confidence interval, 0.53 to 0.78), with an 83% overall test agreement and a 68% positive test agreement...
  90. ncbi Age-appropriate use of human papillomavirus vaccines in the U.S
    Philip E Castle
    Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, DHHS, Bethesda, MD 20892 7234, USA
    Gynecol Oncol 114:365-9. 2009
    ..It is increasingly evident that prophylactic HPV vaccines will provide the greatest public health or population benefit only when delivered to adolescent, mostly HPV-naive women...
  91. ncbi Viral load of human papillomavirus and risk of CIN3 or cervical cancer
    Attila T Lorincz
    Digene Corporation, Gaithersburg, MD 20708, USA
    Lancet 360:228-9. 2002
    ..Results were stratified into four groups (RLU/PC 1 to <10, 10 to <100, 100 to <1000, > or = 1000). Although presence of HPV strongly increased risk of CIN3+, high viral load did not further predict risk of CIN3+...
  92. ncbi The potential utility of HPV genotyping in screening and clinical management
    Philip E Castle
    Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Department of Health and Human Services, 6120 Executive Boulevard, Room 5004, EPS MSC 7234, Bethesda, MD 20892 7234, USA
    J Natl Compr Canc Netw 6:83-95. 2008
    ..However, several practical considerations must be addressed before HPV genotyping can be used in screening and clinical management...
  93. ncbi A 2-year prospective study of human papillomavirus persistence among women with a cytological diagnosis of atypical squamous cells of undetermined significance or low-grade squamous intraepithelial lesion
    Martyn Plummer
    International Agency for Research on Cancer, Lyon, France
    J Infect Dis 195:1582-9. 2007
    ..Most infections and associated lesions clear spontaneously. It is important to define the determinants and timing of clearance, so that viral persistence can be recognized and managed...
  94. ncbi Invited commentary: is monitoring of human papillomavirus infection for viral persistence ready for use in cervical cancer screening?
    Philip E Castle
    Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD 20892 7234, USA
    Am J Epidemiol 168:138-44; discussion 145-8. 2008
    ..Investigators will need to address these and other key issues in order to realize the potential utility of HPV viral monitoring for improving the accuracy of cervical cancer screening...
  95. ncbi Re: Human papillomavirus in oral exfoliated cells and risk of head and neck cancer
    Philip E Castle
    J Natl Cancer Inst 96:1181-2; author reply 1182-3. 2004
  96. ncbi Impact of 6-month frozen storage of cervical specimens in alkaline buffer conditions on human papillomavirus genotyping
    Brandon J LaMere
    Regional Laboratory, Kaiser Permanente Northern California, Berkley, CA, USA
    J Virol Methods 151:298-300. 2008
    ..Six-month frozen storage of cervical specimens at alkaline pH had little impact on testing for HPV genotypes among hc2-positive women using this HPV genotyping method...
  97. ncbi Human papillomavirus genotyping after denaturation of specimens for Hybrid Capture 2 testing: feasibility study for the HPV persistence and progression cohort
    Brandon J LaMere
    Regional Laboratory, Kaiser Permanente Northern California, Berkley, CA, USA
    J Virol Methods 146:80-5. 2007
    ..07), suggesting that these differences represented chance (intra-test variability). It can be concluded that residual Hybrid Capture-positive specimens can be genotyped by PCR after Hybrid Capture 2 processing...
  98. ncbi HPV-16 L1 VLP vaccine elicits a broad-spectrum of cytokine responses in whole blood
    Ligia A Pinto
    SAIC Frederick, Inc NCI Frederick, Room 120, Building 469, Frederick, MD 21702, USA
    Vaccine 23:3555-64. 2005
    ....
  99. ncbi Epidemiologic profile of type-specific human papillomavirus infection and cervical neoplasia in Guanacaste, Costa Rica
    Rolando Herrero
    Proyecto Epidemiologico Guanacaste, Fundacion INCIENSA, San Jose, Costa Rica
    J Infect Dis 191:1796-807. 2005
    ..CONCLUSIONS: We confirmed the bimodal age pattern of HPV infection in Guanacaste and the sexually transmitted nature of both oncogenic and nononcogenic HPV types...
  100. ncbi Semiquantitative human papillomavirus type 16 viral load and the prospective risk of cervical precancer and cancer
    Philip E Castle
    Digene Corporation, 1201 Clopper Road, Gaithersburg, MD 20878, USA
    Cancer Epidemiol Biomarkers Prev 14:1311-4. 2005
    ..008), possibly diminishing any additional risk for > or =CIN3 attributable to higher HPV16 viral loads...
  101. ncbi Chapter 7: Achievements and limitations of cervical cytology screening
    Henry C Kitchener
    Academic Unit of Obstetrics and Gynaecology, University of Manchester, St Mary s Hospital, Whitworth Park, Manchester, UK
    Vaccine 24:S3/63-70. 2006
    ..The increasing rate of human papillomavirus (HPV) testing and the prospect of prophylactic vaccination will change the way cervical cytology is used, possibly giving way to HPV testing as the primary test in secondary prevention...